	US 12,312,410 B2
	Anti-CD39 antibodies
Yangsheng Qiu, Shanghai (CN); Meiling Sun, Shanghai (CN); Roumei Xing, Shanghai (CN); Dan Xu, Shanghai (CN); Yufei Shi, Shanghai (CN); Jinfeng Zhao, Shanghai (CN); Qinglin Du, Shanghai (CN); Zhihao Wu, Shanghai (CN); Rui Gao, Shanghai (CN); Robert H. Arch, Shanghai (CN); and Hongtao Lu, Shanghai (CN)
Assigned to ELPISCIENCE (SUZHOU) BIOPHARMA, LTD, (CN)
Appl. No. 17/283,553
Filed by ELPISCIENCE (SUZHOU) BIOPHARMA, LTD., Jiangsu (CN); and ELPISCIENCE BIOPHARMA, LTD., Shanghai (CN)
PCT Filed Aug. 26, 2020, PCT No. PCT/CN2020/111219 § 371(c)(1), (2) Date Apr. 8, 2021, PCT Pub. No. WO2021/037037, PCT Pub. Date Mar. 4, 2021.
Claims priority of application No. PCT/CN2019/102778 (WO), filed on Aug. 27, 2019; and application No. 202010842863.9 (CN), filed on Aug. 20, 2020.
Prior Publication US 2021/0388105 A1, Dec. 16, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01)

CPC C07K 16/2896 (2013.01) [A61K 39/3955 (2013.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

24 Claims

1. An antibody or an antigen-binding fragment thereof capable of specifically binding to human CD39, comprising a heavy chain variable region comprising HCDR1, HCDR2 and HCDR3 and a light chain variable region comprising LCDR1, LCDR2 and LCDR3, wherein

a) the HCDR1 comprises the amino acid sequence of DTFLH (SEQ ID NO: 4); and

b) the HCDR2 comprises the amino acid sequence of X₅₈IDPAX₅₉X₆₀NIKYDPKFQG (SEQ ID NO: 151); and

c) the HCDR3 comprises the amino acid sequence of SPYYYGSGYRIFDV (SEQ ID NO: 16); and

d) the LCDR1 comprises the amino acid sequence of SAFSSVNYMH (SEQ ID NO: 22); and

e) the LCDR2 comprises the amino acid sequence of TTSNLAS (SEQ ID NO: 28); and

f) the LCDR3 comprises the amino acid sequence of QQRSTYPFT (SEQ ID NO: 34);

wherein X₅₈is R or K, X₅₉is N, G, S or Q, X₆₀is G, A or D.